Oxaliplatin Injection 100Mg

Oxaliplatin Injection 100Mg is a chemotherapy pharmaceutical product widely used in the treatment of colorectal cancer and other advanced gastrointestinal malignancies. It belongs to the platinum-based class of anticancer agents and is commonly administered in combination with other chemotherapy medicines such as fluorouracil and leucovorin. This injectable formulation is primarily indicated for metastatic colorectal cancer and as adjuvant therapy following surgical removal of tumors to reduce the risk of cancer recurrence.

Oxaliplatin works by forming cross-links within the DNA strands of cancer cells, thereby interfering with DNA replication and transcription. This action inhibits the growth and spread of malignant cells, ultimately leading to cancer cell death. Due to its targeted cytotoxic mechanism, oxaliplatin plays a critical role in modern oncology treatment protocols. The injection is administered intravenously under strict medical supervision in a controlled clinical setting to ensure accurate dosing and patient safety.

Oxaliplatin Injection 100 mg should only be administered by qualified oncology healthcare professionals experienced in chemotherapy management. Dosage is determined based on body surface area, overall health status, and treatment regimen. Regular monitoring is essential to manage potential side effects and ensure optimal therapeutic outcomes. As a trusted pharmaceutical product in cancer therapy, oxaliplatin remains an important component in comprehensive colorectal cancer treatment strategies.

Product Features

• Contains Oxaliplatin 100 mg, a platinum-based anticancer agent
• Used in colorectal and gastrointestinal cancer treatment
• Administered via intravenous infusion
• Commonly combined with other chemotherapy agents
• Manufactured under stringent pharmaceutical quality standards

How It Helps

• Inhibits cancer cell growth and replication
• Damages cancer cell DNA to prevent tumor progression
• Supports combination chemotherapy regimens
• Helps reduce recurrence risk after surgery